Published in Clin Pharmacol Ther on November 01, 1994
Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol (2009) 4.16
Biomarkers of environmental tobacco smoke exposure. Environ Health Perspect (1999) 3.50
Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ (2014) 2.83
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther Drug Monit (2009) 1.89
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Hair as a biomarker for exposure to tobacco smoke. Tob Control (2002) 1.63
Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health (1999) 1.52
Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control (2004) 1.47
Salivary cotinine concentration versus self-reported cigarette smoking: Three patterns of inconsistency in adolescence. Nicotine Tob Res (2006) 1.47
D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend (2009) 1.27
Do initial responses to drugs predict future use or abuse? Neurosci Biobehav Rev (2012) 1.26
The genetics of substance dependence. Annu Rev Genomics Hum Genet (2012) 1.25
A new look at quantifying tobacco exposure during pregnancy using fuzzy clustering. Neurotoxicol Teratol (2011) 1.20
Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol (2001) 1.17
A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics (2008) 1.14
A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.13
Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res (2010) 1.09
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther (2007) 1.06
Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. Eur J Clin Pharmacol (2009) 1.04
Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiol Biomarkers Prev (2009) 1.04
The Twin Research Registry at SRI International. Twin Res Hum Genet (2012) 1.04
Nicotine metabolism and addiction among adolescent smokers. Addiction (2012) 1.04
A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. Pharmacogenomics J (2009) 1.03
Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Behav Genet (2011) 1.03
Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers. Cancer Epidemiol Biomarkers Prev (2008) 1.02
Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J Pharmacol Exp Ther (2008) 1.01
CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenet Genomics (2012) 1.00
Calibrating self-reported measures of maternal smoking in pregnancy via bioassays using a Monte Carlo approach. Int J Environ Res Public Health (2009) 0.99
Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence. Psychopharmacology (Berl) (2011) 0.99
Nicotine exacerbates brain edema during in vitro and in vivo focal ischemic conditions. J Pharmacol Exp Ther (2009) 0.99
Simultaneous and sensitive measurement of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.98
The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev (2014) 0.97
The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol (2012) 0.95
Environmental and biological monitoring of exposures to PAHs and ETS in the general population. Environ Int (2010) 0.92
Nicotinic receptors in neurodegeneration. Curr Neuropharmacol (2013) 0.91
Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS One (2013) 0.90
Children's exposure to secondhand and thirdhand smoke carcinogens and toxicants in homes of hookah smokers. Nicotine Tob Res (2014) 0.89
Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. Neurotox Res (2011) 0.88
Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev (2012) 0.87
Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. Eur J Clin Pharmacol (2006) 0.87
Determinants of plasma concentrations of nicotine and cotinine during cigarette smoking and transdermal nicotine treatment. Eur J Clin Pharmacol (1997) 0.86
Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract (2010) 0.85
Nicotine and cotinine in infants dying from sudden infant death syndrome. Int J Legal Med (2007) 0.84
Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol (2010) 0.84
CYP2A6 genotype but not age determines cotinine half-life in infants and children. Clin Pharmacol Ther (2013) 0.84
Estimation of cutoff values of cotinine in urine and saliva for pregnant women in Poland. Biomed Res Int (2013) 0.84
Fatal intravenous injection of electronic nicotine delivery system refilling solution. J Med Toxicol (2014) 0.84
Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cells. Neurotoxicology (2008) 0.83
Biochemical estimation of noncompliance with smoking of very low nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev (2014) 0.83
Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers. Nicotine Tob Res (2015) 0.81
Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. CNS Drugs (2015) 0.81
Novel insights on the effect of nicotine in a murine colitis model. J Pharmacol Exp Ther (2012) 0.81
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neurosci (2015) 0.80
Utility and cutoff value of hair nicotine as a biomarker of long-term tobacco smoke exposure, compared to salivary cotinine. Int J Environ Res Public Health (2014) 0.80
Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. Pharmacogenet Genomics (2016) 0.79
Finding genomic function for genetic associations in nicotine addiction research: the ENCODE project's role in future pharmacogenomic analysis. Pharmacol Biochem Behav (2014) 0.78
Oral fluid nicotine markers to assess smoking status and recency of use. Ther Drug Monit (2011) 0.78
Overview of Cotinine Cutoff Values for Smoking Status Classification. Int J Environ Res Public Health (2016) 0.77
Prenatal tobacco exposure is related to neurobehavioral modifications in infants of adolescent mothers. Clinics (Sao Paulo) (2011) 0.77
Neurobiology of nAChRs and cognition: a mini review of Dr. Jerry J. Buccafusco's contributions over a 25 year career. Biochem Pharmacol (2011) 0.77
Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. Pharmacol Biochem Behav (2016) 0.77
The Influence of Puff Characteristics, Nicotine Dependence, and Rate of Nicotine Metabolism on Daily Nicotine Exposure in African American Smokers. Cancer Epidemiol Biomarkers Prev (2016) 0.77
N-acetyltransferase 1 polymorphism increases cotinine levels in Caucasian children exposed to secondhand smoke: the CCAAPS birth cohort. Pharmacogenomics J (2014) 0.76
Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer. Pharmacogenet Genomics (2017) 0.75
Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction. EXCLI J (2017) 0.75
Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans. Pharmacogenet Genomics (2017) 0.75
The effectiveness of breath carbon monoxide analyzer in screening for environmental tobacco smoke exposure in Saudi pregnant women. Ann Thorac Med (2013) 0.75
A randomized controlled trial of a videoconferencing smoking cessation intervention for Korean American women: preliminary findings. Int J Womens Health (2016) 0.75
Genetics of tobacco use. Tob Induc Dis (2004) 0.75
Estimation of Saliva Cotinine Cut-Off Points for Active and Passive Smoking during Pregnancy-Polish Mother and Child Cohort (REPRO_PL). Int J Environ Res Public Health (2016) 0.75
Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. Drug Metab Dispos (2016) 0.75
Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [(11)C]DAA1106 Positron Emission Tomography Study. Neuropsychopharmacology (2017) 0.75
Does a Race-Gender-Age Crossover Effect Exist in Current Cigarette Smoking Between Non-Hispanic Blacks and Non-Hispanic Whites? United States, 2001-2013. Nicotine Tob Res (2016) 0.75
Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer. Am J Public Health (2015) 0.75
Measuring nicotine intake among highly-dependent adolescent smokers: comparability of saliva and plasma cotinine concentrations. Pharmacol Biochem Behav (2007) 0.75
Comparative assessment of salivary cotinine level and psychological dependence among tobacco users. Dent Res J (Isfahan) (2017) 0.75
Biomarkers of Exposure to New and Emerging Tobacco and Nicotine Delivery Products. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Ethnic differences in current smoking and former smoking in the Netherlands and the contribution of socioeconomic factors: a cross-sectional analysis of the HELIUS study. BMJ Open (2017) 0.75
Population Pharmacokinetic Model of Transdermal Nicotine Delivered from a Matrix-Type Patch. Br J Clin Pharmacol (2017) 0.75
Non-smoking pregnant women and their fetuses are exposed to environmental tobacco smoke as a result of living in multiunit housing. J Expo Sci Environ Epidemiol (2016) 0.75
Assessment of serum cotinine in patients with chronic heart failure: self-reported versus objective smoking behaviour. Clin Res Cardiol (2012) 0.75
Nicotine metabolism and intake in black and white smokers. JAMA (1998) 5.03
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med (1983) 4.80
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
Cotinine disposition and effects. Clin Pharmacol Ther (1983) 3.26
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther (1988) 3.05
Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med (1986) 2.87
Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther (1984) 2.43
Dose-responses from multi-model inference for the non-cancer disease mortality of atomic bomb survivors. Radiat Environ Biophys (2012) 2.31
Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther (1993) 2.30
Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther (1994) 2.28
Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health (1988) 2.16
The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet (1992) 2.15
Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther (1999) 2.14
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol (1999) 1.73
Prospective multicenter evaluation of colon capsule examination indicated by colonoscopy failure or anesthesia contraindication. Endoscopy (2012) 1.63
Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol (1993) 1.60
Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther (1982) 1.60
Preliminary observations on the effects of age on oropharyngeal deglutition. Dysphagia (1989) 1.53
Adequacy of "hot biopsy" for the treatment of diminutive polyps: a prospective randomized trial. Am J Gastroenterol (1989) 1.49
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med (1989) 1.48
Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. JAMA (1986) 1.45
Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther (1987) 1.45
Deficient C-oxidation of nicotine. Clin Pharmacol Ther (1995) 1.43
Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther (1995) 1.28
Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther (2000) 1.26
A reordering of human chromosome 19 long-arm DNA markers and identification of markers flanking the myotonic dystrophy locus. Genomics (1989) 1.24
Bioavailability of sublingual buprenorphine. J Clin Pharmacol (1997) 1.21
Post-Chornobyl thyroid cancers in Ukraine. Report 1: estimation of thyroid doses. Radiat Res (2005) 1.20
Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol (2001) 1.17
Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol (1997) 1.17
Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest (1994) 1.16
Internal exposure from the ingestion of foods contaminated by 137Cs after the Chernobyl accident--report 2. Ingestion doses of the rural population of Ukraine up to 12 y after the accident (1986-1997). Health Phys (2000) 1.14
Daily use of smokeless tobacco: systemic effects. Ann Intern Med (1989) 1.13
Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking. Clin Pharmacol Ther (1984) 1.11
Comparison of EPR occupational lifetime external dose assessments for Mayak nuclear workers and film badge dose data. Radiat Environ Biophys (2006) 1.11
Nicotine and carbon monoxide intake from high- and low-yield cigarettes. Clin Pharmacol Ther (1984) 1.10
Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther (1998) 1.10
Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. Epidemiology (1994) 1.10
Stable isotope studies of nicotine kinetics and bioavailability. Clin Pharmacol Ther (1991) 1.09
Time trends of thyroid cancer incidence in Belarus after the Chernobyl accident. Radiat Res (1999) 1.06
Disposition kinetics and effects of intravenous nicotine. Clin Pharmacol Ther (1980) 1.06
Radiation doses from Ural region. Nature (1996) 1.06
Nicotine dependence and tolerance in man: pharmacokinetic and pharmacodynamic investigations. Prog Brain Res (1989) 1.06
Visual cognition: a new look at the two-visual systems model. Neuropsychologia (2005) 1.05
Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking. J Pharmacol Exp Ther (1990) 1.04
Disposition kinetics and effects of menthol. Clin Pharmacol Ther (1999) 1.03
Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem Res Toxicol (1992) 1.03
Verification of external exposure assessment for the upper Techa riverside by luminescence measurements and Monte Carlo photon transport modeling. Radiat Environ Biophys (2003) 1.03
Blood cotinine levels as indicators of smoking treatment outcome. Clin Pharmacol Ther (1984) 1.02
Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther (2000) 1.01
Sympathomimetic effects of paraxanthine and caffeine in humans. Clin Pharmacol Ther (1995) 0.99
Investigations of thermoluminescence dosimetry in the Techa river flood plain: analysis of the new results. Radiat Prot Dosimetry (2002) 0.99
Issues in the reconstruction of environmental doses on the basis of thermoluminescence measurements in the Techa riverside. Health Phys (1998) 0.98
Releasable suture technique for trabeculectomy. Indian J Ophthalmol (1997) 0.98
Important factors governing exposure of the population and countermeasure application in rural settlements of the Russian Federation in the long-term after the Chernobyl accident. J Environ Radioact (2001) 0.97
Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol (2001) 0.97
Decrease in the size of the myotonic dystrophy CTG repeat during transmission from parent to child: implications for genetic counselling and genetic anticipation. Am J Med Genet (1993) 0.96
Mechanistic modelling in large case-control studies of lung cancer risk from smoking. Stat Med (2002) 0.96
Depth-dose distribution in bricks determined by thermoluminescence and by Monte-Carlo calculation for external gamma-dose reconstruction. Appl Radiat Isot (1996) 0.96
Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther (1998) 0.96
Studies on the Mayak nuclear workers: dosimetry. Radiat Environ Biophys (2002) 0.95
First international intercomparison of luminescence techniques using samples from the Techa River Valley. Health Phys (2002) 0.95
Ophthalmoplegic migraine: inflammatory neuropathy with secondary migraine? Can J Neurol Sci (2007) 0.95
Miller-Dieker syndrome. Detection of a cryptic chromosome translocation using in situ hybridization in a family with multiple affected offspring. Am J Dis Child (1993) 0.94
Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther (1985) 0.94
Photon dose conversion coefficients for human teeth in standard irradiation geometries. Health Phys (2005) 0.94
Breast cancer risk in atomic bomb survivors from multi-model inference with incidence data 1958-1998. Radiat Environ Biophys (2011) 0.94
Thyroid cancer risk to children calculated. Nature (1998) 0.93
Stochastic aspects and uncertainties in the prechemical and chemical stages of electron tracks in liquid water: a quantitative analysis based on Monte Carlo simulations. Radiat Environ Biophys (2000) 0.92
Saliva cotinine levels as a function of collection method. Addiction (1997) 0.92
Influence of tobacco abstinence on the disposition kinetics and effects of nicotine. Clin Pharmacol Ther (1987) 0.92
Dose-dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther (1990) 0.92
[Arthritis caused by Yersinia enterocolitica with the presence of intra-articular germs]. Rev Rhum Mal Osteoartic (1986) 0.92
Individual differences in nicotine kinetics and metabolism in humans. NIDA Res Monogr (1997) 0.92
Pilot study of the Urals population by tooth electron paramagnetic resonance dosimetry. Radiat Environ Biophys (1996) 0.91
Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. Chem Res Toxicol (1994) 0.91
Exact solutions of the clonal expansion model and their application to the incidence of solid tumors of atomic bomb survivors. Radiat Environ Biophys (1997) 0.90
Nicotine content of the eclipse nicotine delivery device. Am J Public Health (1997) 0.90
Stable isotope method for studying transdermal drug absorption: the nicotine patch. Clin Pharmacol Ther (1991) 0.90
EPR dose reconstruction for Russian nuclear workers. Health Phys (2000) 0.90
Bioavailability and absorption kinetics of nicotine following application of a transdermal system. Br J Clin Pharmacol (1993) 0.89
Cotinine effects on nicotine metabolism. Clin Pharmacol Ther (1997) 0.89
A convenient synthesis of quinones from hydroquinone dimethyl ethers. Oxidative demethylation with ceric ammonijm nitrate. J Org Chem (1976) 0.89
Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control (2004) 0.89
Strontium metabolism in teeth and enamel dose assessment: analysis of the Techa river data. Radiat Environ Biophys (2000) 0.88
Structure-activity relationships of the classic hallucinogens and their analogs. NIDA Res Monogr (1994) 0.88
Intravenous nicotine retards transdermal absorption of nicotine: evidence of blood flow--limited percutaneous absorption. Clin Pharmacol Ther (1992) 0.88
The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy. Osteoporos Int (2012) 0.88
Clinical pharmacology of oral cotinine. Drug Alcohol Depend (2000) 0.88
Methamphetamine quantitative urine concentrations during a controlled trial of fluoxetine treatment. Preliminary analysis. Ann N Y Acad Sci (2000) 0.88
[Treatment of proximal humeral fractures by Telegraph nail: prospective study of 34 cases]. Rev Chir Orthop Reparatrice Appar Mot (2007) 0.88
Justification of remediation strategies in the long term after the Chernobyl accident. J Environ Radioact (2010) 0.87
Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther (2006) 0.87
Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther (1981) 0.87
Reply to Little et al.: dose-responses from multi-model inference for the non-cancer disease mortality of atomic bomb survivors. Radiat Environ Biophys (2013) 0.86
Incorporation of isotopically labeled cocaine and metabolites into human hair: 1. dose-response relationships. J Anal Toxicol (1996) 0.86
Primary hepatocellular carcinoma in workers exposed to vinyl chloride: a report of two cases. Cancer (1997) 0.86
Ion-pair extraction of thiocyanate from plasma and its gas chromatographic determination using on-column alkylation. Anal Chem (1984) 0.86
The lived experience of hope among parents of a child with Duchenne muscular dystrophy: perceiving the human being beyond the illness. Chronic Illn (2009) 0.86